URINALYSIS
conceptual economic model. Health Technol Assess. 2024;28(77):1-109. doi:10.3310/PTMV8524
6 UKHSA. Antibiotic resistant infections continue to rise. (
Gov.uk, 2023)
www.gov. uk/government/news/antibiotic-resistant- infections-continue-to-rise
7 UKHSA. UKHSA publishes latest survey on healthcare-associated infections. (Gov. uk, 2025)
www.gov.uk/government/ news/ukhsa-publishes-latest-survey-on- healthcare-associated-infections
8 NHS England. New awareness campaign to help reduce hospital admissions for urinary tract infections. (NHSE, 2023) www.
england.nhs.uk/2023/10/new-awareness- campaign-to-help-reduce-hospital- admissions-for-urinary-tract-infections/
9 Sturgess I, Weinbren M, Clarke K. Automated urinalysis: a role in managing sepsis. Pathology in Practice. 2014 November;15(4):118-121
The Mast Uri Connect is Mast Group’s latest evolution of its system.
directly from the urine sample, providing culture and sensitives simultaneously. This removes the requirement for an initial culture that is routinely required for other secondary care methodologies, resulting in a 24-hour reduction in turnaround time. This will directly aid primary care, where results can currently take anywhere from three to five days to land back at a GP’s desk.
One area that we are continuing to develop with the Mast Uri Connect is our AMR portfolio. We are currently working on reformulations of our current AMR screening offerings, including updating our carbapenem-resistant Enterobacteriaceae (CRE) product to focus on carbapenemase-producing Enterobacteriaceae (CPE) instead. A poster detailing its development can be found on the Mast Group website.14
collaboration of healthcare professionals, government bodies and medical diagnostics developers, the burden of UTIs will almost certainly be reduced. This article has been written in partnership with the general practitioners of Castlefields Health Centre, a primary care community health centre providing a vital service to over 15,000 patients in its local area of Runcorn, Cheshire. I want to thank the team for their comments, which have been indispensable in gaining a better understanding of the challenges they face with UTIs and antibiotic stewardship.
References 1 Clinical Knowledge Summary. Urinary tract
This
is as well as looking to expand the range, to allow for the identification of more common AMR mechanisms. Much like with our alignment to EUCAST expert reading rules, we focus on antibiotic stewardship, in the shared goal of combating AMR.
Conclusions The burden of UTIs is felt at every level of care in the UK, from the immense number of cases to the increasing resistance to treatment. Advancements in technologies with an emphasis on proper antimicrobial stewardship are the key areas to be focused on to help relieve healthcare burden and improve patient outcomes. Government-led initiatives paint a bright future for the advancement of the healthcare system, and through the
infection (lower) - men: How common is it? (NICE, 2025)
www.cks.nice.org.uk/ topics/urinary-tract-infection-lower-men/ background-information/prevalence/
2 Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol. 2020;38(11):2669- 2679. doi:10.1007/s00345-019-03071-4
3 Martin S. What’s new in antimicrobial stewardship? (UK Clinical Pharmacy Association, 2023) www.
ukclinicalpharmacy.org/clinical/infection/ whats-new-in-antimicrobial-stewardship/
4 Palin V, Mölter A, Belmonte M, et al. Antibiotic prescribing for common infections in UK general practice: variability and drivers. J Antimicrob Chemother. 2019;74(8):2440-2450. doi:10.1093/jac/ dkz163
5 Tomlinson E, Ward M, Cooper C, et al. Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and
WWW.PATHOLOGYINPRACTICE.COM AUGUST 2025
10 Department of Health and Social Care. 10 Year Health Plan for England: fit for the future. (
Gov.uk, 2025)
www.gov.uk/ government/publications/10-year-health- plan-for-england-fit-for-the-future
11 Department of Health and Social Care. Pharmacy First: what you need to know. (
Gov.uk, 2024)
https://healthmedia.blog.
gov.uk/2024/02/01/pharmacy-first-what- you-need-to-know/
12 Department of Health and Social Care. Confronting antimicrobial resistance 2024 to 2029 (
Gov.uk, 2024)
www.gov.uk/ government/publications/uk-5-year-action- plan-for-antimicrobial-resistance-2024- to-2029
13 European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints and dosing of antibiotics. (EUCAST, 2025)
www.eucast.org/clinical_breakpoints
14 King N, Ellwood L. Development of Mast Uri Plates for Urinary Tract Infections AMR Screening: Carbapenemase- Producing Enterobacteriaceae (CPE). (Mast Group, 2024)
www.mast-group. com/uk/news-events/news/development- of-mast-uri-plates-for-urinary-tract- infections-amr-screening-carbapenemase- producing-enterobacteriaceae-cpe/
Jonathan Shaw is a Product Specialist at Mast Group. He has worked with the Mast Uri System and Mast Uri Connect for over four years, starting his career as an R&D laboratory
technician, transitioning to an R&D scientist and then making the jump to the marketing team. Prior to this, he obtained MSc in Molecular Oncology from the University of Liverpool in 2020.
0151 933 7277
sales@mast-group.com
www.mast-group.com
51
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
